Inactive

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish aneff ective, eff icient, integrated pharmacy benefits program for the Military Health System(MHS) which includes th... The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish aneff ective, eff icient, integrated pharmacy benefits program for the Military Health System(MHS) which includes the purchase pharmaceutical agents. The law and implementingregulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy andTherapeutics (P&T) Committee will consider the relative clinical eff ectiveness and relativecost eff ectiveness of pharmaceutical agents in a therapeutic class in recommending theselection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF),Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&TCommittee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within DrugClasses identified for placement on the UF has been issued to obtain quotes from industry.The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements(UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP)based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2025 newly approved drugs will be reviewed: The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions,important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9103. a. Alyftrek - Cystic Fibrosis Agents - NA b. Attruby - Neurological Agents Misc – NA c. Crenessity - Endocrine Agents Miscellaneous - NA d. Danziten - Oncological Agents - NA e. Emrosi -Antibiotics - Tetracyclines f. Hympavzi - Antihemophilic Factors – NA g. Imkeldi – Oncological Agents – Chronic Myelogenous Leukemia h. Nypozi - White Blood Cell Stimulants - Filgrastims i. Omni pod 5 Libre2Plus G6 - Insulins - Miscellaneous Insulin Device j. Revuforj - Oncological Agents – NA k. Tryngolza - Antilipidemics-2 – NA l. Wezlana - Targeted Immunomodulatory Biologics - IL-23 Pre-quotation teleconference is on January 8, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submittedvia e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.